MBEC Versus MBIC: the Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology

Lara Thieme 1*, Anita Hartung 1, Kristina Tramm 1, Mareike Klinger-Strobel 1, Klaus D. Jandt 2, Oliwia Makarewicz 1 and Mathias W. Pletz 1

Abstract

Background: Biofilms are communities of aggregated, matrix-embedded microbial cells showing a high tolerance to an in principle adequate antibiotic therapy, often resulting in treatment failure. A major challenge in the management of biofilm-associated infections is the development of adequate, standardized biofilm susceptibility testing assays that are clinically meaningful, i.e. that their results correlate with treatment outcome. Different biofilm susceptibility endpoint parameters like the minimal biofilm eradication concentration (MBEC) or the minimal biofilm inhibitory concentration (MBIC) have been suggested as a guide for treatment of biofilm-associated infections, however with inconsistent perception and use among biofilm researchers, leading to confusion and contradictions among different anti-biofilm component studies and clinical trials.

Findings: Evaluation of anti-biofilm effects is mostly based on the untreated reference growth control biofilm measured at the same endpoint as the treated biofilm, neglecting the possible change of the untreated reference biofilm from the time point of pre-antimicrobial exposure to the measured endpoint. In this commentary, we point out the importance of individual quantification of mature, established biofilms before antimicrobial treatment for each biofilm model in order to draw conclusions on the measured biofilm effect size, i.e. biofilm reducing (MBEC) or biofilm inhibitory (MBIC) effects.

Conclusion: The assessment of pre-treatment biofilms contributes to a standardized use of biofilm susceptibility endpoint parameters, which is urgently needed to improve the clinical validity of future anti-biofilm assays.

Keywords: Biofilm-associated infections, Biofilm susceptibility testing, Biofilm susceptibility endpoint parameters, MBEC, MBIC

Background

Biofilms are matrix-embedded communities of microbial cells that are attached to each other and/or on a surface [1]. Biofilms protect enclosed bacterial cells against the immune system and an in principle adequate antibiotic therapy, often resulting in treatment failure, relapsing infections and increased mortality [1]. The minimal inhibitory concentrations (MIC) of antibiotics are routinely determined using planktonic bacteria and do not match the concentrations that are required to prevent, inhibit, diminish or eradicate biofilms [2].

A major challenge in the management of biofilm-associated infections (BAI) is the development of adequate, standardized biofilm susceptibility testing assays that are clinically meaningful, i.e. that their results correlate with treatment outcome [3, 4]. Over the last years, a multitude of diverse laboratory methods to assess anti-biofilm treatments has been developed. Each method has its own benefits and drawbacks as critically discussed elsewhere, with the overall consensus that
there is currently no optimal biofilm method available mimicking the in vivo biofilm setting of human BAI [3, 5, 6]. Different biofilm susceptibility endpoint parameters have been suggested as a guide for treatment of BAI, like the minimal biofilm eradication concentration (MBEC), the minimal biofilm inhibitory concentration (MBIC), the biofilm bactericidal concentration (BBC) or the biofilm prevention concentration (BPC) [2]. However, the definition and interpretation of these parameters differ greatly among publications and none of the official agencies, e.g. EUCAST or CLSI, have yet set up standardized definitions of biofilm endpoint parameters likewise the MIC. While some researchers define the MBEC as the lowest concentration of an antimicrobial substance that eradicates 99.9% of biofilm-embedded bacteria (3 log₁₀ reduction in CFU/mL) compared to growth controls [7], others define the former as the BBC in line with the minimal bactericidal concentration (MBC) on planktonic level and refer to the MBEC in the context of complete eradication of the biofilm [2, 8]. Inhibitory effects on biofilm formation are commonly assessed by the MBIC, which is the lowest concentration of an antimicrobial substance at which there is no time-dependent increase in the mean number of biofilm viable cells [2]. In contrast to the MBIC, the BPC determines at which antimicrobial substance concentration the cell density of a planktonic culture is sufficiently reduced in order to prevent biofilm formation [2].

In this commentary, we point out the importance of individual quantification of mature, established biofilms before antimicrobial treatment for each biofilm model in order to draw conclusions on the measured biofilm effect size, i.e. biofilm reducing or biofilm inhibitory effects.

**Findings**

Importantly, all of the above parameters, except for the BPC, analyse the activity of antimicrobial substances on mature, established biofilms, so the experimental set-up to assess either biofilm reducing or inhibitory effects is in principle the same, regardless of the method of choice of biofilm growth and assay readout (Fig. 1). After establishment - while even the time of biofilm maturation varies strongly between different research groups -, biofilms are treated with the respective antimicrobial substance for a variable period of time (hours to days), followed by assessment of the treated and untreated biofilms by e.g. CFU/mL determination, image acquisition or staining and photometric measurement (e.g. resazurin or crystal violet). Evaluation of anti-biofilm effects is thereby mostly based on the untreated reference growth control biofilm measured at the same endpoint as the treated biofilm [7, 9–11], assuming that the constitution (e.g. viable cell numbers, total biomass etc.) of the untreated reference growth control biofilm is stable from the time point of pre-antimicrobial exposure to the measured endpoint. Four theoretical scenarios showing the consequences of stable and unstable quantities of untreated reference biofilm viable cells (CFU/mL) over the course of the experiment for the interpretation of anti-biofilm effects are listed in Table 1. Provided the established biofilm had a starting quantity of 10⁵ CFU/mL before antimicrobial treatment (Table 1, scenario A), the quantification of 10⁸ CFU/mL of the untreated biofilm at the measured endpoint reveals that the biofilm without the addition of antibiotics increased by 3 log₁₀ in CFU/mL. The treated biofilm with 10⁵ CFU/mL at the measured endpoint, however, implies no increase in the mean number of biofilm viable cells, making this scenario a classic example for the determination of inhibitory effects. The further growth of the biofilm was inhibited with addition of the antimicrobial substance by 3 log₁₀ in CFU/mL in scenario A, but the biofilm was not reduced by 3 log₁₀ in CFU/mL, which would be the conclusion if the untreated reference growth control biofilm is regarded only at the measured endpoint, but not before antimicrobial exposure. Scenario B illustrates an unstable quantity of the untreated reference biofilm over the course of the experiment as well, but in a smaller magnitude. If the untreated reference biofilm at the time point of pre-antimicrobial exposure and at the measured

---

**Table 1**

| Scenario | Description | untreated biofilm | treated biofilm |
|----------|-------------|-------------------|----------------|
| A        | Stable      | 10⁸ CFU/mL        | 10⁵ CFU/mL     |
| B        | Unstable    | 10⁵ CFU/mL        | 10⁸ CFU/mL     |

**Fig. 1** Reducing versus inhibitory effects on mature biofilms. Green indicates viable cells, red indicates dead cells. ABx = antimicrobial treatment.
Table 1 Interpretation of the anti-biofilm effect size based on different scenarios of starting viable cell numbers before treatment

| Scenario A | Scenario B | Scenario C | Scenario D |
|------------|------------|------------|------------|
| **At measured endpoint** | **Pre-antimicrobial exposure** | **Pre-antimicrobial exposure** | **Pre-antimicrobial exposure** |
| **Untreated** | $10^7$ CFU/mL | $10^6$ CFU/mL | $10^5$ CFU/mL | $10^8$ CFU/mL |
| **Treated** | $10^5$ CFU/mL | $10^5$ CFU/mL | $10^7$ CFU/mL | $10^8$ CFU/mL |
| **Interpretation** | $3 \log_{10}$ biofilm reduction | $3 \log_{10}$ inhibition of biofilm growth (MBIC) | $2 \log_{10}$ biofilm reduction | $3 \log_{10}$ biofilm reduction (MBEC or BBC) |

MBIC Minimal biofilm inhibitory concentration, MBEC Minimal biofilm eradication concentration, BBC Biofilm bactericidal concentration

endpoint is composed of $10^7$ CFU/mL and $10^8$ CFU/mL, respectively, the untreated biofilm increased by $1 \log_{10}$ CFU/mL in this time span. With the same readout of the treated biofilm at the measured endpoint of $10^5$ CFU/mL, this scenario indicates that the biofilm was reduced by $2 \log_{10}$ in CFU/mL (from $10^7$ to $10^5$ CFU/mL) with the addition of the antimicrobial substance. Notably, only the starting quantity of the established, mature biofilm changed, but not the final results at the measured endpoint of this theoretical anti-biofilm assay. Only if the untreated reference biofilm is stable in CFU/mL numbers in the time span of pre-antimicrobial exposure and assay readout (scenario C), the interpretation of the anti-biofilm effect size ($3 \log_{10}$ reduction with a decrease of $10^8$ to $10^5$ CFU/mL) is the same when evaluating the effect based on the reference biofilm at the measured endpoint or the time point before antimicrobial exposure. If the untreated reference biofilm shows a higher viable cell quantity before antimicrobial exposure than at the time point of readout (scenario D), the decrease of viable cell numbers independent on antimicrobial treatment needs to be considered for the interpretation of the anti-biofilm effect size. In scenario D, this means the biofilm quantity decreased treatment-independent from $10^9$ CFU/mL to $10^8$ CFU/mL, leading to a $3 \log_{10}$ reduction from $10^8$ to $10^5$ CFU/mL due to antimicrobial treatment. Above scenarios illustrate that only after the anti-biofilm experiment has been performed and, essentially, had included an assessment of the established biofilm before antimicrobial exposure, one can clearly say i) whether a biofilm reducing or inhibitory effect has taken place, ii) how high the magnitude of the analysed effect is. Researchers should therefore match the according biofilm susceptibility parameter to the observed effect based on the quantification of the reference growth control biofilm before and after treatment.

To assess how the starting number of biofilm viable cells may influence the interpretation of the anti-biofilm effects measured in our biofilm model, we determined the CFU/mL of untreated reference biofilms of five different bacterial species before and after potential antimicrobial exposure (Fig. 2). In our model, biofilms are grown for 48 h followed by incubation of antimicrobial substance for 24 h, resulting in 72 h of growth of untreated reference biofilms at the measured endpoint. Bacterial suspensions (0.5 McFarland) of three clinical isolates of each *Enterococcus faecium, Enterococcus faecalis, Staphylococcus aureus, Pseudomonas aeruginosa* and *Klebsiella pneumoniae* prepared in Müller Hinton broth or Todd Hewitt broth (both Karl Roth, Karlsruhe, Germany) for enterococci, respectively, were inoculated

![Fig. 2 Biofilm viable cell numbers (CFU/mL) after 48 h and 72 h of growth. Shown are the mean values with ranges of triplicates. An unpaired t-test was performed to analyse significant differences (P-value < 0.05) between 48 h and 72 h of growth. ns = no significance](image)
in triplicates in plastic microtiter plates (Greiner Bio-one, Frickenhausen, Germany). Biofilms were grown at 37 °C, 5% CO₂ without shaking for 48 h and 72 h with change of medium after 48 h to mock antimicrobial treatment. After 48 h and 72 h, respectively, biofilms were washed, resuspended and selected 10-fold dilutions were plated for determination of CFU/mL. 80% of the tested isolates showed no significant increase in CFU between both time points (Fig. 2). For two strains (EFL67230 and SA4002), CFU₇₂₉h was significantly increased compared to CFU₄₈ₙₒ, however below 1 log₁₀ and therefore not influencing the interpretation of the results in terms of reducing or inhibiting effects. One *E. faecium* isolate (EF24498) showed a significant decrease in CFU/mL, but again below 1 log₁₀. The constancy of biofilm cell numbers from the time point of pre-antimicrobial exposure to the measured endpoint implies the determination of biofilm reducing instead of inhibiting effects in our model (Table 1, scenario C). A decrease in viable cell numbers of the treated biofilm compared to the untreated reference biofilm at the measured endpoint (which has the equal quantity as the untreated reference biofilm pre-antimicrobial exposure) can clearly be related to a reduction of the biofilm due to antimicrobial treatment. If viable biofilm cell numbers were increasing between 48 h and 72 h, either the effect magnitude of the reducing effect would change (Table 1, scenario B) or inhibiting instead of reducing effects would be analysed (Table 1, scenario A), making it necessary to determine the anti-biofilm effect size based on the quantification of the established, mature biofilm before antimicrobial treatment. Importantly, the constancy of the reference biofilm may not be the case for other methods of biofilm growth, e.g. dynamic biofilm reactors where biofilms are grown under constant nutrient flow [3], highlighting the importance of individual quantification of mature, pre-treatment biofilms for each biofilm model.

**Conclusions**

Above scenarios elucidate another point of many current difficulties in biofilm methodology. Presently, biofilm susceptibility endpoint parameters are inconsistently perceived, used and interpreted among biofilm researchers. For example, Sandoe et al. quantified their peg biofilms before and after exposure to ampicillin, showing a significant reduction in CFU/mL numbers, yet using the MBIC as biofilm susceptibility endpoint parameter to describe their results [11]. To overcome this lack of consistency, standardized methods with accurate and precise definitions of biofilm susceptibility endpoint parameters are urgently needed, reducing confusion and contradictions among different anti-biofilm component studies. For the clinical evaluation of anti-biofilm compounds intended for therapy of BAI, it is crucial to determine whether a drug is able to penetrate and eradicate, in part or completely, the biofilm structure or is only able to inhibit its further growth.

The current insufficient evidence to recommend antimicrobics on the basis of biofilm susceptibility testing is mainly attributed to the deficit of proper methodology representing in vivo biofilms [5]. The fact that the very few clinical trials addressing BAI have not measured biofilm eradicative but inhibitory effects might contribute to the poor observed correlation between biofilm susceptibility testing and clinical outcome [10–12]. Commercially available anti-biofilm test kits like the MBEC Assay®, formerly the Calgary Biofilm Device (Innovotech, Edmonton, Canada), show increasing rates of use in biofilm research [6], however neglect the potential problem of not measuring reducing, but inhibitory effects. Although the datasheet of the MBEC Assay® recommends a biofilm growth check before antimicrobial treatment [13], most publications do not take those values into account for the interpretation of anti-biofilm effects [10–12, 14]. We therefore highly encourage biofilm researchers to assess established biofilms before antimicrobial exposure, independent on the method of choice for biofilm growth and assay readout, to bring more clarity to their measured biofilm effect size and biofilm susceptibility parameters. The assessment of pre-treatment biofilms will contribute to a standardized use of biofilm susceptibility endpoint parameters, which is urgently needed to improve the comparability of anti-biofilm studies and to make progress in the development of clinically meaningful anti-biofilm assays.

**Abbreviations**

BAI: Biofilm-associated infection; BPC: Biofilm bactericidal concentration; BFC: Biofilm formation concentration; CFU: Colony forming unit; CLSI: Clinical & Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; MBEC: Minimal biofilm eradication concentration; MBIC: Minimal biofilm inhibitory concentration; MIC: Minimal inhibitory concentration.

**Acknowledgements**

Not applicable.

**Authors’ Contributions**

LT conceptualized the article, designed and performed the experiments; analysed and interpreted the data; wrote and revised the manuscript. AH and KT revised and critically discussed the article; performed the experiments; analysed the data. MKS, KDJ, OM and MWP revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

**Authors’ Information**

LT is a member of the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Biofilm Study Group.

**Funding**

This work was supported by the Federal Ministry of Education and Research, Germany (grant numbers 01K1501 and 01EO1502) and the German Research Foundation (grant numbers PL 320/3–1 and PL 320/3–2).
Availability of Data and Materials
All data generated or analysed during this study are included in this published article.

Ethics Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Competing Interests
The authors declare that they have no competing interests.

Author details
1Institute for Infectious Diseases and Infection Control, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany. 2Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Löbdergraben 32, Jena 07743, Germany.

Received: 27 June 2019 Accepted: 8 August 2019

Published online: 13 September 2019

References
1. Bjarnsholt T, Alhede M, Alhede M, Eickhard-Sorensen SR, Moser C, Kuhl M, et al. The in vivo biofilm. Trends Microbiol. 2013;21(9):466–74.
2. Macia MD, Rojo-Moliner E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20(10):981–90.
3. Azeredo J, Azavedo NF, Briandet R, Cerca N, Coenye T, Costa AR, et al. Critical review on biofilm methods. Curr Rev Microbiol. 2017;43(3):313–51.
4. Wiegand C, Volpel A, Ewald A, Remesch M, Kuever J, Bauer J, et al. Critical physiological factors influencing the outcome of antimicrobial testing according to ISO 22196 / JIS Z 2801. PLoS One. 2018;13(3):e0194335.
5. Coenye T, Goeres D, Van Bambeke F, Bjarnsholt T. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? Clin Microbiol Infect. 2018;24(6):570–2.
6. Magana M, Sereti C, Ioannidis A, Mitchell CA, Ball AR, Magiorkinis E, et al. Options and limitations in clinical investigation of bacterial biofilms. Clin Microbiol Rev. 2018;31(3). https://doi.org/10.1128/CMR.00084-16.
7. Dall GF, Tsang SJ, Gwynne PJ, MacKenzie SP, Simpson A, Breusch SJ, et al. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. J Antimicrob Chemother. 2018;73(7):1830–40.
8. Cruz CD, Shah S, Tammela P. Defining conditions for biofilm inhibition and eradication assays for gram-positive clinical reference strains. BMC Microbiol. 2018;18(1):173.
9. Brady AJ, Laverty G, Gilpin DF, Kearney P, Tunney M. Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MICT? J Med Microbiol. 2017;66(4):461–9.
10. Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth M, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2011;46(2):184–92.
11. Sandoe JA, Wysome J, West AP, Heritage J, Wilcox MH. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother. 2006;57(4):677–70.
12. Yau YC, Rajjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015;14(2):262–6.
13. http://www.innovotech.ca/wp-content/uploads/2019/02/MBEC-Procedural-Manual-v2.0.pdf. Accessed 21 May 2019.
14. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42(5):1915–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.